Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

Preliminary results announced

Profound Medical issued a press release stating it expects total revenue for the third quarter ended September 30, 2026 to be in the range of $9.8 million to $10.0 million. The company characterized these figures as preliminary and unaudited and said actual revenues may differ. Profound indicated it will report full third quarter 2026 financial results after market close on Thursday, November 5th and host a conference call at 4:30 p.m. ET to review the results and business developments. (Source: company press release.)

Sources: S1

Growth metrics cited by the company

Profound presented year-over-year and sequential growth comparisons in the release. The company said year-over-year growth for Q3-2026 is expected to increase approximately 85% to 89% compared with $5.3 million in the third quarter of 2025, and sequential quarter-over-quarter growth is expected to increase approximately 292% to 300% compared with $2.5 million in the second quarter of 2026. The release also states the expected revenue is approximately 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million. (Source: company press release.)

Sources: S1

Profitability indicator highlighted

The company said Q3-2026 gross margin is again expected to exceed 70%, which Profound framed as reflecting continued progress in its commercial operations and scale. This gross margin expectation is described as part of the preliminary results. (Source: company press release.)

Sources: S1

Company commentary and next steps

Profound's CEO and Chairman, Arun Menawat, is quoted in the release describing the expected increase in revenue as a historic milestone and linking it to commercial momentum, increased commercial activity across the installed base, and new customer accounts. The company reiterated that the figures are preliminary and unaudited and that consensus estimates are third-party analyst work which the company does not endorse, adopt, or control. (Source: company press release.)

Sources: S1

What remains uncertain

• All figures presented in the press release are described by the issuer as preliminary and unaudited; the company states actual revenues may differ.
• Consensus comparisons cited in the release reference third-party analyst estimates compiled by Bloomberg, which the company states it does not endorse, adopt, or control.
• The release contains forward-looking statements and the company lists a range of risks and assumptions that could cause actual results to differ materially; those risks are not independently verified in this draft.